Product news

Share this article:
Amgen said the European Commission has granted a conditional marketing authorization for Vectibix (panitumumab) as monotherapy for the treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.